Patent: 11,026,997

Summary for Patent: 11,026,997

Title:	Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
Abstract:	The present invention provides, among other things, methods of treating post-cardiac injury syndrome (PCIS) or pericarditis, comprising a step of administering to a subject in need of treatment an interleukin-1 receptor-Fc fusion protein at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more signs and symptoms of pericarditis relative to a control.
Inventor(s):	Tessari Eben, Paolini John
Assignee:	Regeneron Pharmaceuticals, Inc.
Application Number:	US16143391
Patent Claims:	see list of patent claims

United States Patent 11,026,997 Claims and U.S. Patent Landscape: What’s Covered, Who Owns It, and Where Generics or Licensing Risks Exist

Executive summary

• Patent US 11,026,997 is a U.S. granted patent with claims that are central to evaluating (1) enforceability across competitors, (2) whether the claim scope is broad enough to cover at-risk products, and (3) whether competitors can design around via claim-structure changes or alternative processes/formulations.
• A complete, accurate claim-by-claim analysis and landscape mapping to Orange Book / FDA listings, Paragraph IV challenges, biosimilar analogs, and litigation depends on the exact claim set and the bibliographic record (assignee, filing/priority, expiration, and international family).
• Because the prompt does not include the full claim text (the user message ends at “The claims are: ” without the claims), an end-to-end analysis cannot be produced without risking factual errors, mis-stating claim scope, or mis-identifying key related patents and enforcement targets.

Details for Patent 11,026,997

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kiniksa Pharmaceuticals (uk), Ltd.	ARCALYST	rilonacept	For Injection	125249	February 27, 2008		2038-09-26

International Patent Family for US Patent 11,026,997

Country	Patent Number	Estimated Expiration
Canada	3075538
Denmark	3687562
European Patent Office	3687562
European Patent Office	4541367
Spain	3023044